Authors: Isaacsohn, J Insull, W Stein, E Kwiterovich, P Ma, P Brazg, R Dujovne, CA Shan, M Shugrue-Crowley, E Ripa, S Tota, R

Citation: J. Isaacsohn et al., Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia, CLIN CARD, 24(9), 2001, pp. 1-9

Authors: Davidson, MH Toth, P Weiss, S McKenney, J Hunninghake, D Isaacsohn, J Donovan, JM Burke, SK

Citation: Mh. Davidson et al., Low-dose combination therapy with colesevelam hydrochloride and lovastatineffectively decreases low-density lipoprotein cholesterol in patients withprimary hypercholesterolemia, CLIN CARD, 24(6), 2001, pp. 467-474

Authors: Isaacsohn, J Zinny, M Mazzu, A Lettieri, J Heller, AH

Citation: J. Isaacsohn et al., Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults, EUR J CL PH, 56(12), 2001, pp. 897-903

Authors: Insull, W Isaacsohn, J Kwiterovich, P Ma, P Brazg, R Dujovne, C Shan, M Shugrue-Crowley, E Ripa, S Tota, R

Citation: W. Insull et al., Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial, J INT MED R, 28(2), 2000, pp. 47-68

Authors: Davidson, MH Dillon, MA Gordon, B Jones, P Samuels, J Weiss, S Isaacsohn, J Toth, P Burke, SK

Citation: Mh. Davidson et al., Colesevelam hydrochloride (Cholestagel) - A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects, ARCH IN MED, 159(16), 1999, pp. 1893-1900

Authors: Stein, E Isaacsohn, J Stoltz, R Mazzu, A Liu, MC Lane, C Heller, AH

Citation: E. Stein et al., Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mgdose of cerivastatin in patients with primary hypercholesterolemia, AM J CARD, 83(10), 1999, pp. 1433-1436